Covidien plc

Covidien — Q2 2013 Earnings Presentation

39 slides from Covidien's earnings presentation, May 3, 2013

  1. Slide 1: Covidien Excluding Pharmaceuticals

    Exhibit 99.1 Covidien Excluding Pharmaceuticals May 3, 2013

  2. Slide 2: Forward-Looking Statements

    Nene a... Forward-Looking Statements This presentation contains certain “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995. These statements are based on current i and are subject to risks, uncertainty and changes in eeu mslances| wh

  3. Slide 3: Forward-Looking Statements (continued)

    Lene... Forward-Looking Statements (continued) Recalls or safety alerts and negative publicity relating to Covidien or its products Product liability losses and other litigation liability Prices for oil, gas and other commodities Divestitures of some of our businesses or product lines Our ability to

  4. Slide 4: Covidien intends to spin off its Pharmaceuticals segment

    4 | Covidien intends to spin off its Pharmaceuticals segment into a stand-alone public company. Management anticipates that the transaction will be in the form of a distribution that will be tax-free to U.S. shareholders of publicly traded stock in the new pharmaceuticals company. Covidien currently

  5. Slide 5: Operating and financial leverage targets

    5 | – Operating leverage Mid-single digit sales growth Double-digit EPS growth – Financial leverage Improve return on invested capital (ROIC) over time Return cash to shareholders

  6. Slide 6: Quarterly net sales

    FY 10 FY11 FY 12 Q1 2012 Q2 2012 Q3 2012 Q4 2012 Q1 2013 Q2 2013 6 | $2,567 $2,408 $2,499 $2,506 $2,438 $2,530

  7. Slide 7: FY FY11 FY Q1 2012 Q2 2012 Q3 2012 Q4 2012 Q1 2013 |

    FY 10 FY11 FY 12 Q1 2012 Q2 2012 Q3 2012 Q4 2012 Q1 2013 7 |

  8. Slide 8: FY FY11 FY Q1 2012 Q2 2012 Q3 2012 Q4 2012 Q1 2013 |

    FY 10 FY11 FY 12 Q1 2012 Q2 2012 Q3 2012 Q4 2012 Q1 2013 8 |

  9. Slide 9: FY FY11 FY Q1 2012 Q2 2012 Q3 2012 Q4 2012 Q1 2013 |

    FY 10 FY11 FY 12 Q1 2012 Q2 2012 Q3 2012 Q4 2012 Q1 2013 9 |

  10. Slide 10: FY FY11 FY Q1 2012 Q2 2012 Q3 2012 Q4 2012 Q1 2013 |

    FY 10 FY11 FY 12 Q1 2012 Q2 2012 Q3 2012 Q4 2012 Q1 2013 10 |

  11. Slide 11: FY FY11 FY Q1 2012 Q2 2012 Q3 2012 Q4 2012 Q1 2013 |

    FY 10 FY11 FY 12 Q1 2012 Q2 2012 Q3 2012 Q4 2012 Q1 2013 11 |

  12. Slide 12: Quarterly adjusted EPS

    Q1 2012 Q2 2012 Q3 2012 Q4 2012 Q1 2013FY 10 FY11 FY 12 12 | $0.97 $0.97 $0.86 $0.91 $0.87

  13. Slide 13: Capital Strategy

    Capital Strategy Remain committed to return at least 50% of free cash flow to shareholders every year through di and share — Currently executing on $2 billion stock buyback authorization — Board recently approved additional $3 billion buyback authorization — Expect to increase dividend payout ratio

  14. Slide 14: Annual dividend per share

    2008 2009 2010 2011 2012 2013* $0.64 $0.64 $0.72 $0.80 $0.90 14 | $1.04

  15. Slide 15: Tyco Tax Sharing Agreement (TSA)

    Nene a... Tyco Tax Sharing Agreement (TSA) ae the Tyco TSA, orien (COV), Tyco International (TYC) and TE TEL) ar p for 42%, 27% and 31%, respectively, of U.S. income tax liabilities prior to the 2007 Tyco spin. Mallinckrodt (MNK) will not be a party to this agreement. Upon separation from COV, MNK w

  16. Slide 16: 2013 Segment Sales Guidance

    Nene a... 2013 Segment Sales Guidance Medical Supplies 1% to 2% Medical Devices 4% to 6% 4 , 2013 levels.

  17. Slide 17: 2013 Guidance

    Lene... 2013 Guidance 2013 2011 2012 Guidance Adjusted Operating Margin* 23.2% 23.2% 22.0% to 22.5% Adjusted Tax Rate** 18.8% 17.3% 17.0% to 17.5% Weighted Avg. Diluted Shares Outstanding (MM) 497 486 470 to 475 measure. Ed covipien 17 | May, 2018

  18. Slide 18: Foreign Exchange / Medical Device Tax

    Foreign Exchange / Medical Device Tax E FX expected to negatively impact EPS by approximately $0.15 -$0.20 m | — 125 - 175bp unfavorable to sales growth rate in FY2013 Medical device tax expected to increase SG&A by $75 - $100MM annvaly — Only three quarters of impact in FY2013 1, 2013 levels. Ed co

  19. Slide 19: Appendix

    Covidien Excluding Pharmaceuticals Appendix May 3, 2013

  20. Slide 20: 2010 Financial Results

    oO O—O—O——————OOOOOOOOOOO———OO—O—OOOOOOOOOEOEOO—O—E—E—EeEeeeeee 2010 Financial Results 2010 Non- 2010 2010 Reclassto Adjusted GAAP As $ Millions GAAP D.O. for D.O. Adjustments Adjusted Net Sales $10,429 $(1,991) $ 8,438 $ 8,438 Gross Profit* 5,805 (860) 4,945 $33 4,978 % of Sales 55.7% 58.6% 59.0% S

  21. Slide 21: 2010 Financial Results

    oO O—O—O——————OOOOOOOOOOO———OO—O—OOOOOOOOOEOEOO—O—E—E—EeEeeeeee 2010 Financial Results 2010 Non- 2010 2010 Reclassto Adjusted GAAP As $ Millions, except per share amounts | GAAP D.O. forD.0. Adjustments Adjusted Operating income $2,063 $(342) $1,721 $188 $ 1,909 Net interest expense (177) (7) (G42)

  22. Slide 22: 2011 Financial Results

    oO O—O—O——————OOOOOOOOOOO———OO—O—OOOOOOOOOEOEOO—O—E—E—EeEeeeeee 2011 Financial Results 2011 Non- 2011 2011 Reclassto Adjusted GAAP As $ Millions GAAP D.O. forD.0. Adjustments Adjusted Net Sales $11,574 $(1,967) $ 9,607 $ 9,607 Gross Profit* 6,578 (857) 5,721 $34 5,755 % of Sales 56.8% 59.5% 59.9% Se

  23. Slide 23: 2011 Financial Results

    Lene... 2011 Financial Results 2011 Non- 2011 2011 Reclassto Adjusted GAAP As $ Millions, except per share amounts | GAAP. D.O. for D.O. Adjustments Adjusted Operating income $2,375 $ (333) $2,042 $183 $ 2,225 Net interest expense (181) (6) (184) (184) Other income __ 22, — = _ 22 __ 6 __ 28° Pre-ta

  24. Slide 24: 2012 Financial Results

    Lene... 2012 Financial Results 2012 Non- 2012 2012 Reclassto Adjusted GAAP As $ Millions GAAP D.O. forD.0. Adjustments Adjusted Net Sales $11,852 $(2,001) $ 9,851 $ 9,851 Gross Profit* 6,814 (907) 5,907 $37 5,944 % of Sales 57.5% 60.0% 60.3% Selling, Gen’| & Admin** 3,686 (C22) 3,261 (749) 3,191 % o

  25. Slide 25: 2012 Financial Results

    Lene... 2012 Financial Results 2012 Non- 2012 2012 Reclassto Adjusted GAAP As $ Millions, except per share amounts | GAAP’ D.O. for D.O. Adjustments Adjusted Operating income $2,414 $(329) $2,085 $201 $ 2,286 Net interest expense (190) (@) (191) (191) Other income _ 25 _= — a5 __fil)) __ 24 Pre-tax

  26. Slide 26: Q1 2012 Financial Results

    Lene... Q1 2012 Financial Results Qi Q1 2012 Non- Qt 2012 2012 Reclassto Adjusted GAAP $ Millions GAAP D.O. for D.O. Adjustments Adjusted Net Sales $ 2,898 $(490) $ 2,408 $ 2,408 Gross Profit* 1,701 (219) 1,482 $2 1,484 % of Sales 58.7% 61.5% 61.6% Selling, Gen’l & Admin** 907 (99) 808 (47) 761 % of

  27. Slide 27: Q1 2012 Financial Results

    Lene... Q1 2012 Financial Results Qi Q1 2012 Non- Q1 2012 2012 Reclassto Adjusted GAAP $ Millions, except per share amounts | GAAP D.O. for D.O. Adjustments Adjusted Operating income $ 636 $(79) $ 557 $ 59 $ 616 Net interest expense (45) (a) (46) (46) Other income 2 1 __ 1 __ ee Pre-tax income 593 (

  28. Slide 28: Q2 2012 Financial Results

    a ———————————————EEEEE_EEE__________________efe_e_ Q2 2012 Financial Results a2 Q2.2012 Non- Q2 2012 2012 Reclassto Adjusted GAAP $ Millions GAAP D.O. forD.0. Adjustments Adjusted Net Sales $ 2,946 $(508) $2,438 $ 2,438 Gross Profit* 1,706 (238) 1,468 $ 3 1,471 % of Sales 57.9% 60.2% 60.3% Selling,

  29. Slide 29: Q2 2012 Financial Results

    Lene... Q2 2012 Financial Results Q2 Q2 2012 Non- Q2 2012 2012 Reclassto Adjusted GAAP $ Millions, except per share amounts | GAAP. D.O. for D.O. Adjustments Adjusted Operating income $609 $ (94) $ 515 $ 32 $ 547 Net interest expense (45) (4) (47) (47) Other income _ 4 _ = 4 _ 4 _ 8 Pre-tax income 5

  30. Slide 30: Q3 2012 Financial Results

    oO O—O—O——————OOOOOOOOOOO———OO—O—OOOOOOOOOEOEOO—O—E—E—EeEeeeeee Q3 2012 Financial Results Q3 Q3 2012 Non- Q3 2012 2012 Reclassto Adjusted GAAP $ Millions GAAP D.O. for D.O. Adjustments Adjusted Net Sales $3,007 $(501) $2,506 $ 2,506 Gross Profit* 1,739 (228) 1,511 a5 1,516 % of Sales 57.8% 60.3% 60.

  31. Slide 31: Q3 2012 Financial Results

    oO O—O—O——————OOOOOOOOOOO———OO—O—OOOOOOOOOEOEOO—O—E—E—EeEeeeeee Q3 2012 Financial Results Q3 Q3 2012 Non- Q3 2012 2012 Reclassto Adjusted GAAP $ Millions, except per share amounts | GAAP D.O. for D.O. Adjustments Adjusted Operating income $617 $(79) $ 538 $ 42 $ 580 Net interest expense (62) 2 (50)

  32. Slide 32: Q4 2012 Financial Results

    Lene... Q4 2012 Financial Results a4 Q4 2012 Non- Q4 2012 2012 Reclassto Adjusted GAAP $ Millions GAAP D.O. for D.O. Adjustments Adjusted Net Sales $ 3,001 $(602) $ 2,499 $ 2,499 Gross Profit* 1,668 (222) 1,446 $ 27 1,473 % of Sales 55.6% 57.9% 58.9% Selling, Gen’l & Admin** 929 (110) 819 ((:)) 814

  33. Slide 33: Q4 2012 Financial Results

    oO O—O—O——————OOOOOOOOOOO———OO—O—OOOOOOOOOEOEOO—O—E—E—EeEeeeeee Q4 2012 Financial Results a4 Q4 2012 Non- Q4 2012 2012 Reclassto Adjusted GAAP $ Millions, except per share amounts | GAAP D.O. for D.O. Adjustments Adjusted Operating income $552 $(77) $ 475 $ 68 $ 543 Net interest expense (48) - (48)

  34. Slide 34: Q1 2013 Financial Results

    Lene... Q1 2013 Financial Results Qi Q1 2013 Non- Q1 2013 2013 Reclassto Adjusted GAAP $ Millions GAAP D.O. for D.O. Adjustments Adjusted Net Sales $3,056 $(489) $2,567 $ 2,567 Gross Profit 1,756 (219) 1,537 1,537 % of Sales 57.5% 59.9% 59.9% Selling, Gen’! & Admin 941 (119) 822 822 % of Sales 30.8%

  35. Slide 35: Q1 2013 Financial Results

    Lene... Q1 2013 Financial Results Qi Q1 2013 Non- Q1 2013 2013 Reclassto Adjusted GAAP $ Millions, except per share amounts | GAAP’ D.O. for D.O. Adjustments Adjusted Operating income $658 $(62) $ 596 $8 $ 604 Net interest expense (49) 1 (48) (48) Other income _1 — — il __ 1 Pre-tax income 610 (61)

  36. Slide 36: Q2 2013 Financial Results

    Lene... Q2 2013 Financial Results Q2 Q2 2013 Non- Q2 2013 2013 Reclassto Adjusted GAAP As $ Millions GAAP D.O. for D.O. Adjustments Adjusted Net Sales $3,103 $(573) $2,530 $ 2,530 D.O. = Discontinued Operations Ed covipien May 3, 2013

  37. Slide 37: Annual sales growth by product line

    37 | 2010 2011 2012 Medical Devices 11% / 8% 17% / 13% 4% / 6% Endomechanical 8% / 5% 9% / 6% – / 2% Soft Tissue Repair 6% / 3% 5% / 2% (2%) / 1% Energy Devices 14% / 12% 18% / 15% 12% / 14% Oximetry & Monitoring 19% / 17% 13% / 11% 2% / 3% Airway & Ventilation 1% / (2%) (2%) / (6%) (1%) / 1% Vascul

  38. Slide 38: Quarterly sales growth by product line

    38 | Q1 2012 Q2 2012 Q3 2012 Q4 2012 Q1 2013 Q2 2013 Medical Devices 6% / 5% 7% / 7% 4% / 8% (1%) / 2% 8% / 9% 4% / 6% Endomechanical 2% / 2% 4% / 5% 1% / 6% (7%) / (3%) 7% / 8% 4% / 6% Soft Tissue Repair (1%) / (1%) 1% / 2% (1%) / 4% (6%) / (1%) 3% / 4% – / 2% Energy Devices 19% / 19% 12% / 14% 10%

  39. Slide 39: Non-GAAP Financial Measures

    Lene... Non-GAAP Financial Measures y “non-GAAP” ti id isi The financial substitute for financial generally non-GAAP pany g 's historical to competitors’ parency yy init i king, including jidien’ to fest * ts ( gains that will be recorded in i itis it the impact of those items in the forecast. The f

Covidien — Q2 2013 Earnings Presentation on 6ix